When Parkinson's or another neurodegenerative disease is diagnosed, patients always ask: "And now what? What will happen? What can be expected from the disease?" For neurologists, however, it is not possible to answer these questions precisely, as "the evolution of patients tends to be very varied: some experience no change over the years, while others end up with dementia or in a wheelchair", explained Ane Murueta-Goyena, researcher in the UPV/EHU's department of Neurosciences.
Today, identifying Parkinson's patients at risk of cognitive impairment poses a major challenge, yet this is necessary when it comes to providing more effective clinical treatments and stepping up clinical trials. In fact, Dr Ane Murueta-Goyena, in collaboration with Biobizkaia's research staff, wanted to see "whether the visual system can enable this deterioration to be predicted, in other words, what future the patient can expect within a few years". The thickness of the retina was used for this purpose.
The retina is a membrane located at the back of the eyeball, it is related to the nervous system and comprises several layers. During the study, a cohort of Parkinson's patients had the thickness of the innermost layer of their retinas measured using optical coherence tomography. This type of tomography is a routinely used instrument in ophthalmological tests, as it allows high-resolution, repeatable and accurate measurements to be made. So the evolution of this retinal layer was analysed and compared in people with and without Parkinson's disease over the 2015-2021 period. The results of the analysis of the images of the retinal layers of Parkinson's patients were also confirmed in a UK hospital.
The results showed that the retinal layer is noticeably thinner in Parkinson's patients. It was also observed that "during the initial phases of the disease it is in the retina where the greatest neurodegeneration is detected, and, from a given moment onwards, when the layer is already very thin, a kind of stabilising of the neurodegeneration process takes place. Retinal thinning and cognitive impairment do not occur simultaneously. The initial changes in the retina are more evident and then, over the years, patients are observed to worsen clinically in both cognitive and motor terms", explained Murueta-Goya. In other words, the slower retinal layer thickness loss is associated with faster cognitive decline; this slowness is linked to greater severity of the disease".
The researcher has attached great importance to the results: "We have obtained information on the progression of the disease, and the tool we are proposing is non-invasive and available at all hospitals." The results need to be validated internationally and "by slightly improving the resolution of the technology, we will be closer to validating the method for monitoring the neurodegeneration that takes place in Parkinson's disease". The researcher also revealed that they are continuing the research on another cohort of patients and that funding is the key.
Additional information
This study was conducted in collaboration with the Ikerbasque Research Associate at Biobizkaia Iñigo Gabilondo, and was based on the data obtained from the cohort of patients from hospitals in Bizkaia (Cruces, Urduliz and Basurto) and from the hospital in Araba. This has been confirmed by images from a database of Parkinson's patients at the NIHR Biomedical Research Centre at Moorfields Eye Hospital and from the UCL Institute of Ophthalmology.
Dr Ane Murueta-Goyena is a lecturer on the degree course in medicine at the UPV/EHU and is a member of the LaNCE-Neuropharm - GIC 21/133 research group.
Bibliographical reference
Ane Murueta-Goyena, David Romero-Bascones, Sara Teijeira-Portas, J. Aritz Urcola, Javier Ruiz-Martínez, Rocío Del Pino, Marian Acera, Axel Petzold, Siegfried Karl Wagner, Pearse Andrew Keane, Unai Ayala, Maitane Barrenechea, Beatriz Tijero, Juan Carlos Gómez Esteban, Iñigo Gabilondo
Association of retinal neurodegeneration with the progression of cognitive decline in Parkinson's disease
NPJ Parkinson's disease
DOI: 10.1038/s41531-024-00637-x
Image caption: Optical coherence tomography (LaNCE-Neuropharm - GIC 21/133).
